darunavir and HIV
darunavir has been researched along with HIV in 44 studies
Research
Studies (44)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (29.55) | 29.6817 |
| 2010's | 25 (56.82) | 24.3611 |
| 2020's | 6 (13.64) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Armentano, MF; Benedetti, F; Berti, F; Bisaccia, F; Chiummiento, L; Funicello, M; Lupattelli, P; Miglionico, R; Milella, L; Tramutola, F | 1 |
| Agniswamy, J; Ghosh, AK; Hattori, SI; Jadhav, RD; Kovela, S; Mitsuya, H; Osswald, H; Simpson, H; Wang, YF; Weber, IT | 1 |
| Castro, A; Clavero, E; Díaz-Díaz, JL; Mena, A | 1 |
| Mejias, A; Peeples, ME; Ramilo, O; Teng, MN | 1 |
| Siedner, MJ; Triant, VA | 1 |
| Best, BM; Capparelli, EV; Chakhtoura, N; Eke, AC; Kreitchmann, R; Mirochnick, M; Shapiro, DE; Smith, E; Stek, AM; Wang, J | 1 |
| Bickel, M; Gillor, D; Grunwald, S; Härter, G; Hoffmann, C; Krznaric, I; Mueller, MC; Müller, M; Postel, N; Roider, J; Römer, K; Schabaz, F; Schewe, K; Spinner, CD | 1 |
| Devanathan, AS; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kashuba, ADM; Kuruc, JD; Margolis, DM; McGee, KS; McKellar, M; Neo, DT; Robertson, K; Schmitz, JL; Sebastian, J; Shaheen, NJ | 1 |
| Bentz, K; Fanucci, GE; Hu, L; Liu, Z; Pham, L; Savin, DA; Tran, TT | 1 |
| Cory, TJ; Gong, Y; Kumar, S; Li, J; Li, W; Meibohm, B; Midde, NM | 1 |
| Guaraldi, G; Raggi, P | 1 |
| Fulco, PP; Higginson, RT; Kakadiya, PP | 1 |
| Challenger, E; Clotet, B; Curran, A; Khoo, S; Miranda, C; Moltó, J; Ribera, E; Santos, JR; Valle, M | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| DeMasi, R; Kakuda, TN; Mohammed, P; van Delft, Y | 1 |
| Benmarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; Lopez-Cortes, LF; Martín-Peña, R; Pérez-Romero, P; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Afonina, LIu; Voronin, EE | 1 |
| Imai, Y; Kawamoto, M; Kohara, N; Sekiya, H; Togo, M; Yoshimura, H | 1 |
| Antinori, A; Biondi, ML; Di Biagio, A; Penco, G; Sterrantino, G; Zaccarelli, M | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Belkhir, L; Capron, A; De Laveleye, M; Delongie, KA; Elens, L; Haufroid, V; Vandercam, B; Vincent, A; Yombi, J; Zech, F | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
| de Béthune, MP; De Meyer, SM; Miralles, GD; Spinosa-Guzman, S; Vangeneugden, TJ | 1 |
| Cartledge, JD; Lascar, M | 1 |
| Hidalgo Tenorio, C; Pasquau Liaño, J | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| García Deltoro, M | 1 |
| Clotet, B | 1 |
| Arribas, JR | 1 |
| Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H | 1 |
| Baietto, L; Bonora, S; Calcagno, A; Cometto, C; D'Avolio, A; Di Perri, G; Ferramosca, S; Galli, M; Ghisetti, V; Gonzalez de Requena, D; Magnani, S; Rusconi, S; Viganò, O; Vitiello, P | 1 |
| Annemans, L; Hill, AM; Mauskopf, J; Smets, E | 1 |
| Brogan, A; Mauskopf, J; Smets, E; Talbird, SE | 1 |
| Allegri, G; Gebo, K; Hemmett, L; Hill, AM; Löthgren, M; Smets, E | 1 |
| Colin, X; Costagliola, D; Guillon, P; Lafuma, A; Mauskopf, J; Smets, E | 1 |
| Brun-Vézinet, F; Calvez, V; Charpentier, C; Descamps, D; Felices, M; Katlama, C; Lambert-Niclot, S; Landman, R; Larrouy, L; Marcelin, AG; Peytavin, G; Valantin, MA; Yeni, P | 1 |
| Nelson, MR; Waters, L | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Hill, A; Moyle, G | 1 |
| Chapsal, BD; Ghosh, AK; Mitsuya, H; Weber, IT | 1 |
| de Béthune, MP; De Meyer, S; Picchio, G | 1 |
| Morales Conejo, M; Moreno Cuerda, VJ; Rubio García, R | 1 |
Reviews
11 review(s) available for darunavir and HIV
| Article | Year |
|---|---|
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
[Use of darunavir in HIV-infected women during pregnancy].
Topics: Darunavir; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy; Pregnancy Complications, Infectious; Sulfonamides; Treatment Outcome | 2013 |
New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Topics: Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Treatment Outcome | 2008 |
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides | 2008 |
[Resistance to darunavir].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Phenotype; Point Mutation; Pyridazines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Ritonavir; Sulfonamides | 2009 |
A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cost-Benefit Analysis; Darunavir; Drug Costs; HIV; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Ritonavir; Standard of Care; Sulfonamides | 2010 |
New drugs.
Topics: Anti-HIV Agents; Benzophenones; Cytidine Triphosphate; Darunavir; Deoxycytidine; Emtricitabine; HIV; HIV Fusion Inhibitors; HIV Reverse Transcriptase; Humans; Imidazoles; Nitriles; Protease Inhibitors; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Zalcitabine | 2005 |
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Topics: Carbamates; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Structure-Activity Relationship; Sulfonamides | 2008 |
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome | 2008 |
[New therapeutic options in protracted HIV-infected patients with virological failure].
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Organic Chemicals; Peptide Fragments; Practice Guidelines as Topic; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; RNA, Viral; Sulfonamides | 2008 |
Trials
7 trial(s) available for darunavir and HIV
| Article | Year |
|---|---|
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Young Adult | 2018 |
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Cross-Over Studies; Darunavir; Drug Interactions; Ethanolamines; Fluorenes; Healthy Volunteers; HIV; HIV Infections; Humans; Lumefantrine; Malaria; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2013 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2010 |
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pyridines; Pyrones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Other Studies
26 other study(ies) available for darunavir and HIV
| Article | Year |
|---|---|
Synthesis and biological evaluation in vitro and in mammalian cells of new heteroaryl carboxyamides as HIV-protease inhibitors.
Topics: Amides; Binding Sites; Cell Survival; HEK293 Cells; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Molecular Docking Simulation; Protein Structure, Tertiary; Structure-Activity Relationship; Transfection | 2017 |
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
Topics: Antiviral Agents; Chromans; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Protease; HIV Protease Inhibitors; Ligands; Models, Molecular; Molecular Structure; Naphthalenes; Structure-Activity Relationship | 2018 |
Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy.
Topics: Cross-Sectional Studies; Darunavir; Female; HIV; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lipidomics; Lipids; Male; Middle Aged; Viral Load | 2019 |
Live Attenuated Vaccine With a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children.
Topics: Atazanavir Sulfate; Case-Control Studies; Child; Child, Preschool; Darunavir; Gene Deletion; HIV; HIV Infections; Humans; Myocardial Infarction; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses | 2020 |
Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.
Topics: Atazanavir Sulfate; Cardiovascular Diseases; Case-Control Studies; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Myocardial Infarction; Risk Factors | 2020 |
Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Statistics as Topic; Young Adult | 2020 |
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Darunavir; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Tenofovir; Viral Load | 2020 |
Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance.
Topics: Amino Acid Substitution; Darunavir; Drug Resistance, Multiple, Viral; Genetic Variation; HIV; HIV Protease; HIV Protease Inhibitors; Mutation; Protein Conformation | 2020 |
Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
Topics: Cell Line; Cytochrome P-450 CYP3A; Darunavir; Ethanol; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Microsomes, Liver; Molecular Docking Simulation; Monocytes; Ritonavir; Virus Replication | 2017 |
Antiretroviral therapies and cardiovascular risk: True or false?
Topics: Cardiovascular Diseases; Darunavir; HIV; HIV Infections; Humans; Risk Factors | 2017 |
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Topics: Aged; Anti-HIV Agents; Cobicistat; Dabigatran; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir | 2018 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
Topics: Adult; Cohort Studies; Darunavir; DNA, Viral; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Proviruses; Real-Time Polymerase Chain Reaction; Ritonavir; Sulfonamides; Viral Load; Viremia | 2014 |
[HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART].
Topics: AIDS Dementia Complex; Anti-Retroviral Agents; Central Nervous System; Cognition Disorders; Darunavir; Disease Progression; Drug Resistance, Viral; Drug Substitution; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viremia; Zidovudine | 2014 |
Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.
Topics: Adult; Animals; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Italy; Male; Middle Aged; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a pote
Topics: Biomarkers; Chromatography, High Pressure Liquid; Cohort Studies; Darunavir; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Limit of Detection; Male; Middle Aged; Nitriles; Prognosis; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
[Position of darunavir in antiretroviral therapy].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2008 |
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
Topics: Adult; Algorithms; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Prognosis; Retrospective Studies; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Disease Progression; Drug Resistance; Female; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Time Factors; United States; Viral Load; Young Adult | 2010 |
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Darunavir; Drug Costs; Europe; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; United States; Young Adult | 2010 |
Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
Topics: Adult; Antiretroviral Therapy, Highly Active; Budgets; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Darunavir; Drug Costs; Drug Resistance; France; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Models, Statistical; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; RNA, Viral; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.
Topics: Darunavir; Drug Resistance, Viral; Enfuvirtide; Genotype; HIV; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Logistic Models; Peptide Fragments; Point Mutation; Sulfonamides | 2011 |
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |